Comparison of PD-L1 Tumor Cell Expression With 22C3, 28-8, and SP142 IHC Assays Across Multiple Tumor Types

Recommended

Protocol for a MULTI-Centre Feasibility Study to Assess the Use of 99mTc-sestaMIBI SPECT/CT in the Diagnosis of Kidney Tumours (MULTI-MIBI Study)

Phase 1, Open-Label, Dose-Escalation Study on the Safety, Pharmacokinetics, and Preliminary Efficacy of Intravenous Coxsackievirus A21 (V937), With or Without Pembrolizumab, in Patients With Advanced Solid Tumors

Association of Polypharmacy and Potential Drug-Drug Interactions With Adverse Treatment Outcomes in Older Adults With Advanced Cancer

Immune-Related Pan-Cancer Gene Expression Signatures of Patient Survival Revealed by NanoString-Based Analyses

The Antitumor Activity of Human Vγ9Vδ2 T Cells is Impaired by TGF-Β through Significant Phenotype, Transcriptomic, and Metabolic Changes

Neoadjuvant Pembrolizumab in Localized MSI-H/dMMR Solid Tumors

Mitochondrial Related Genome-Wide Mendelian Randomization Identifies Putatively Causal Genes for Multiple Cancer Types

Novel Therapy Afamitresgene Autoleucel Shows Early Potential for Antitumor Activity

Comparison of PD-L1 Tumor Cell Expression With 22C3, 28-8, and SP142 IHC Assays Across Multiple Tumor Types

header-info

Nov, 03, 2022

The study shows that 22C3 is the most sensitive PD-L1 IHC assay for tumor cell expression and returns a positive PD-L1 status more frequently than 28-8, which in turn is positive more often than SP-142.